| Dustin M Logan, PHD | |
|
8201 N Michaelson St, Palmer, AK 99645-8196 | |
| (907) 745-5066 | |
| (907) 746-2851 |
| Full Name | Dustin M Logan |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 9 Years |
| Location | 8201 N Michaelson St, Palmer, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851578512 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 60616291 (Washington) | Secondary |
| 103G00000X | Clinical Neuropsychologist | 121536 (Alaska) | Primary |
| Entity Name | Neurobehavior North Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457621914 PECOS PAC ID: 3870866080 Enrollment ID: O20170911002151 |
News Archive
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
The year 2019 marks 24 years of growth for QPS, LLC, a leading global CRO focused on bioanalytics and clinical trials that accelerate pharmaceutical breakthroughs.
The Intelligent Clinician's Guide to the DSM-5- explores all revisions to the latest version of the Diagnostic and Statistics Manual, and shows clinicians how they can best apply the strong points and shortcomings of psychiatry's most contentious resource.
The National Association of Pharmacy Regulatory Authorities (NAPRA) has issued a directive to the provinces requesting that pharmacists not sell Natural Health Products (NHPs) without a Drug Identification Number (DIN), Natural Product Number (NPN) or Drug Identification Number for Homeopathic Medicine (DIN-HM). NAPRA did not engage in consultations with industry participants who will be adversely affected by this move.
According to a nationwide analysis of physician visit records conducted by a team of researchers at Harvard Medical School and the RAND Corporation, nearly 30 percent of the outpatient opioid prescriptions made out in the United States do not have documented justification for their use.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dustin M Logan, PHD Po Box 3034, Palmer, AK 99645-3034 Ph: (907) 745-5066 | Dustin M Logan, PHD 8201 N Michaelson St, Palmer, AK 99645-8196 Ph: (907) 745-5066 |
News Archive
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
The year 2019 marks 24 years of growth for QPS, LLC, a leading global CRO focused on bioanalytics and clinical trials that accelerate pharmaceutical breakthroughs.
The Intelligent Clinician's Guide to the DSM-5- explores all revisions to the latest version of the Diagnostic and Statistics Manual, and shows clinicians how they can best apply the strong points and shortcomings of psychiatry's most contentious resource.
The National Association of Pharmacy Regulatory Authorities (NAPRA) has issued a directive to the provinces requesting that pharmacists not sell Natural Health Products (NHPs) without a Drug Identification Number (DIN), Natural Product Number (NPN) or Drug Identification Number for Homeopathic Medicine (DIN-HM). NAPRA did not engage in consultations with industry participants who will be adversely affected by this move.
According to a nationwide analysis of physician visit records conducted by a team of researchers at Harvard Medical School and the RAND Corporation, nearly 30 percent of the outpatient opioid prescriptions made out in the United States do not have documented justification for their use.
› Verified 4 days ago